Lenacapavir is a mighty weapon against HIV. How’s the rollout?
An injection of the new drug lenacapavir provides six months of protection against infection by HIV. Osodi Emmanuel/Reuters hide caption toggle caption Osodi Emmanuel/Reuters Kalisizo, Uganda — Along the deeply rutted red dirt roads of central Uganda’s Lake Victoria coast, there is little for miles beyond banana groves and bustling markets. The landscape is unassuming — and very dusty. Yet few places have done more to shape HIV care. Irene knows this well. For the past three years, the soft-spoken 22-year-old, who is HIV-negative, has been a participant in one of the most influential HIV clinical trials. She asked NPR to only use her first name for fear of discrimination within her community, where participating in an HIV trial can lead others to assume she has HIV. She was motivated to participate by her uncle, who lives with HIV. “I can see that his life is so hard. Like he gets strong illnesses and even right now he’s so slim,” she says. “Once you get it, your life changes for the worse.” But HIV is …

